| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
5-HT Receptor
Strictosidinic acid targets the 5-HT (serotonin) receptor pathway. It functions as a selective 5-HT biosynthesis inhibitor by inhibiting the precursor enzyme of 5-HT synthesis, leading to reduced serotonin levels. It has no acetylcholinesterase (AChE) activity, enabling clean serotonergic targeting without cholinergic confounds. It belongs to the secologanin-derived tryptamine-iridoid class. |
|---|---|
| ln Vitro |
In vitro, Strictosidinic acid demonstrates antiradical activity against DPPH with an EC50 of 27.68 μM, which is superior to barakol (39.62 μM). It shows no AChE activity, making it a selective tool for studying serotonergic pathways. The compound's DPPH radical scavenging activity indicates its potential as an antioxidant. It has a promising effect in the central nervous system.
|
| ln Vivo |
When administered intrahippocampally, streptosidinic acid (20 μg/μl) significantly lowers 5-HT levels by 83.5%. Male Wistar rats weighing 200–250 g show a 63.4% reduction in 5-HT levels and a 67.4% reduction in DOPAC values when exposed to 10 mg/kg; ip] streptosidinic acid.
In vivo, Strictosidinic acid causes a significant 83.5% reduction in 5-HT levels following intra-hippocampal injection (20 µg/µl) in male Wistar rats. Intraperitoneal administration (10 mg/kg) causes a 63.4% reduction in 5-HT levels and a 67.4% reduction in DOPAC values. It exhibits peripheral analgesic and antipyretic activity in mice without causing central nervous system sedation. The compound shows promise for research in the central nervous system. |
| Enzyme Assay |
For non-cell-based assays, Strictosidinic acid can be evaluated for its DPPH radical scavenging activity using a standard antioxidant assay. The compound is incubated with DPPH solution at various concentrations, and the decrease in absorbance at 517 nm is measured to calculate the EC50 value. For receptor binding studies, radioligand binding displacement assays using membrane preparations from cells expressing 5-HT receptors can be performed with a suitable radiolabeled ligand. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand, followed by filtration and scintillation counting.
|
| Cell Assay |
For in vitro cellular assays, cells expressing 5-HT receptors or serotonergic neurons can be cultured in appropriate media. To assess the compound's effect on serotonin levels, cells are treated with various concentrations of Strictosidinic acid, and 5-HT content is measured using HPLC or ELISA-based detection. The compound's antioxidant activity can be assessed in cell-based oxidative stress models by measuring reactive oxygen species (ROS) levels using fluorescent probes. Cytotoxicity is assessed using MTT or LDH assays to ensure that observed effects are not due to cell death.
|
| Animal Protocol |
For in vivo animal studies, Strictosidinic acid is typically administered to male Wistar rats (weighing 200-250 g) via intra-hippocampal injection (20 µg/µl) or intraperitoneal injection (10 mg/kg). Following administration, brain tissue (hippocampus or striatum) is collected, and 5-HT and DOPAC levels are measured using HPLC. For analgesic and antipyretic studies, the compound is administered to mice, and pain responses and body temperature are monitored. Dosing regimens vary depending on the specific model and desired exposure levels.
|
| ADME/Pharmacokinetics |
Strictosidinic acid is an orally active compound with a molecular weight of 516.54 and a molecular formula of C26H32N2O9. It is slightly soluble in water (4 g/L at 25°C) and has a density of 1.50±0.1 g/cm3. The compound should be stored at 4°C under nitrogen. In solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month under nitrogen. It is supplied as a powder with ≥98% purity.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Strictosidinic acid has not been extensively reported. As a naturally occurring alkaloid with serotonin-lowering effects, potential adverse effects may include modulation of serotonergic signaling, which could affect mood, appetite, and sleep regulation. The compound is for research use only and is not intended for human consumption. Standard toxicological evaluation would include acute and repeated-dose toxicity studies, as well as assessment of effects on the central nervous system and serotonergic function.
|
| References |
|
| Additional Infomation |
According to reports, strictonucleotides have been found in Ceylon Hunter, Umbrella Hunter, and other organisms with available data.
Strictosidinic acid (CAS 150148-81-5) is a naturally occurring glycosidic monoterpene indole alkaloid isolated from Psychotria myriantha leaves. It serves as a key biosynthetic intermediate in the camptothecin pathway in plants such as Camptotheca acuminata. The compound is characterized by a β-D-glucopyranosyl moiety attached to a strictosidine-derived scaffold. It has been studied for its serotonin-lowering effects and potential applications in central nervous system research. It is available for research purposes only. |
| Molecular Formula |
C26H32N2O9
|
|---|---|
| Molecular Weight |
516.54
|
| Exact Mass |
516.21
|
| CAS # |
150148-81-5
|
| PubChem CID |
21586927
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
792.8±60.0 °C at 760 mmHg
|
| Flash Point |
433.3±32.9 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.692
|
| LogP |
-0.23
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
871
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C=C[C@@H]1[C@@H](C(=CO[C@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)C(=O)O)C[C@H]3C4=C(CCN3)C5=CC=CC=C5N4
|
| InChi Key |
CMMIVMFGFIBAGC-IUNANRIWSA-N
|
| InChi Code |
InChI=1S/C26H32N2O9/c1-2-12-15(9-18-20-14(7-8-27-18)13-5-3-4-6-17(13)28-20)16(24(33)34)11-35-25(12)37-26-23(32)22(31)21(30)19(10-29)36-26/h2-6,11-12,15,18-19,21-23,25-32H,1,7-10H2,(H,33,34)/t12-,15+,18+,19-,21-,22+,23-,25+,26+/m1/s1
|
| Chemical Name |
(2S,3R,4S)-3-ethenyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9360 mL | 9.6798 mL | 19.3596 mL | |
| 5 mM | 0.3872 mL | 1.9360 mL | 3.8719 mL | |
| 10 mM | 0.1936 mL | 0.9680 mL | 1.9360 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
